Navigation Links
Valensa International and Parry Nutraceuticals Join Forces in the Global Natural Products Marketplace
Date:11/26/2008

ORLANDO, Fla., Nov. 26 /PRNewswire/ -- Valensa International (Orlando, USA) and Parry Nutraceuticals (Division of E.I.D. Parry (India) Ltd., Chennai, India), as part of a growth strategy for both companies, have joined forces to usher in the next generation of high-performance nutritional products from plant-derived sources for the condition-specific dietary supplement, functional food and fortified beverage sectors. EID Parry acquired a 48% strategic stake in U.S. Nutraceuticals doing business as Valensa International. Valensa's "Direct to Marketers" product development and business strategy will be expanded under a new management team led by Valensa's President, Dr. Rudi E. Moerck, which includes executives from both companies. With the Valensa investment, Parry becomes a marketing partner and a strategic source of botanical materials and technology for new and existing Valensa products in the fast-growing areas of Omega-3 Essential Fatty Acids (ALA, EPA and DHA); phycocyanins and carotenoids including astaxanthin, lycopene, lutein, zeaxanthin; and others. The new arrangement will strengthen Valensa's ability to market its science-based products globally. Current areas of co-marketing between the companies include astaxanthin and Valensa's patented SpiruZan(TM), a Spirulina/Astaxanthin product co-launched by the two companies at Natural Products Expo East in Boston and HI Europe in Paris.

According to Dr. Rudi E. Moerck, the companies have the same philosophies on sustainable natural product production and focus on natural ingredients made using environmentally responsible technology such as Valensa's organic-certified supercritical carbon dioxide extraction plant in Florida, USA. "Parry Nutraceuticals shares Valensa International's commitment to creating the highest-quality products based on the best available science for the condition-specific human health and nutrition market," he said. "Parry Nutraceuticals is one of the leading producers of ultra-high-quality raw materials including organic Spirulina and carotenoids like beta carotene, astaxanthin, lutein and tomato lycopene. Our cooperative new product development work with Parry will allow us to accelerate our new product development efforts to deliver some of the most exciting new products to the market," he added.

Two Leaders Working Together

Valensa and Parry recently introduced a new dietary supplement, SpiruZan(TM) -- a synergistic complex of micro-algae-based organic Spirulina and Astaxanthin in a small, easy-to-swallow 500 mg caplet presentation. SpiruZan combines the well-known nutritional properties of organic Spirulina with the superior antioxidant properties of Astaxanthin to deliver a "brain+body" supplement that offers enhanced protection from both dietary and environmental stress factors. SpiruZan is now available, providing 1 mg astaxanthin in an organic Spirulina serving. Spirulina product line extensions are also planned.

Parry Nutraceuticals produces the only GRAS-certified Spirulina that is also certified under USDA NOP, OCIA-IFOAM, Naturland and ECOCERT organic standards. Valensa's ingredients are manufactured using the company's DeepExtract(TM) High Pressure Supercritical CO2 Extraction and O2B(TM) Peroxidation Blocker technology, yielding more of the micronutrients contained in natural botanical materials and protecting both products and people from the problems associated with oxidation and rancidification.

    For further information, contact:

    Dr. Rudi E. Moerck, President
    Voice: 210-632-0695
    Fax: 352-483-2095

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Valensa International
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as Lifestyle Support for a Fast-Paced World
2. International Formula Council Statement on Melamine and Infant Formulas
3. Pulmonary Hypertension Treated with Stem Cells : International Medical Team Announces Patient Results in Adult Stem Cell Clinical Study for Pulmonary Hypertension
4. MINRAD International, Inc. Announces Termination of RxElite Holdings Inc. as Anesthetics Distributor for the Human Market in United States
5. Lights Out For Bed Bugs as "BEST YET" Cedar Oil Solution Solves International Bed Bug Dilemma
6. AirMed International wins Air Ambulance of the Year for Second Consecutive Year
7. Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc.
8. Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013
9. Epocrates Offers International Market Research Panel
10. Accreditation to the International Standards Organization for Quality Management Granted to First U.S. Lab
11. MINRAD International, Inc. to Discuss Current Business Conditions on Tuesday, November 25, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... 24, 2017 , ... “End Time GPS”: a dauntless and enlightened study ... Time GPS” is the creation of published author, Wesley Gerboth, a World War II ... and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon ...
(Date:3/24/2017)... ... , ... “The Adventures of Joey, The Dog Who Barks at Puddles”: a ... to the fullest, as God intended. “The Adventures of Joey, The Dog Who Barks ... pursuing her passion for writing, especially about truth and human behavior. , Published by ...
(Date:3/23/2017)... ... ... The physicians of KSF Orthopaedic Center PA are proud to announce the ... located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 inside the ... living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) with an ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... Oklahoma City Convention Center at 10 North Broadway Avenue, will be an educational ... of relevant, practical instruction in the management of chronic pain. , Oklahoma is ...
(Date:3/23/2017)... ... ... of adults are unaware of the dangers that infectious bacteria play in mouth disease, while ... a day that dentists recommend. The ramifications of improper oral upkeep go far beyond bad ... 164 million hours of work each year due to dental issues. That is why Mediaplanet ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , March 23, 2017  Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... Financing Commitment Term Sheet (the "Definitive Financing") it ... of the Company,s stockholders, who are referred to ... a Form 8-K filed with the Securities and ...
(Date:3/23/2017)... The key factors driving the growth ... accelerating economic growth and increasing healthcare expenditure. Some of the ... expectancy of ESRD patients, rising demand for home PD treatment ... of the market is hindered by high treatment costs and ... ...
(Date:3/23/2017)... -- As a result of diagnostic technology increasing ... allergic diseases, cutting edge developments in targeted drugs ... in which pharmaceutical and biotech companies are addressing ... both a high quality meeting and a platform ... research scholars and doctors. The event will also ...
Breaking Medicine Technology: